Astellas makes strategic investment in Poseida

9 August 2023

Japanese drug major Astellas Pharma (TYO: 4503) has announced a strategic investment to support the advancement of Poseida Therapeutics’ (Nasdaq: PSTX) commitment to redefining cancer cell therapy. The news pushed Poseida’s shares up as much as 24% to $2.69.

The investment is comprised of the purchase of 8,333,333 shares of common stock at $3.00 per share for an aggregate purchase price of $25 million and an additional $25 million one-time payment for certain strategic rights, and provided a business update.

The news comes at a useful time for Poseida, which just last month saw its former partner Takeda (TYO: 4502) return rights to the firm’s hemophilia A and PKU gene therapy programs, which it gained from a collaboration and license agreement in October 2021 that was worth a potential $3.6 billion to Poseida.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK